Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Alterity Therapeutics ( (AU:ATH) ) is now available.
Alterity Therapeutics has announced the issuance of over 1.6 billion fully paid ordinary shares, as per the regulations of the Corporations Act. This move is part of the company’s strategy to raise capital without the need for disclosure under Part 6D.2 of the Corporations Act, indicating compliance with necessary legal provisions and transparency requirements, which may impact its financial positioning and stakeholder confidence.
More about Alterity Therapeutics
Alterity Therapeutics is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company is listed on both the Australian Securities Exchange (ASX) and NASDAQ, with its primary market focus on innovative treatments for conditions such as Alzheimer’s and Parkinson’s diseases.
YTD Price Performance: 20.0%
Average Trading Volume: 13,499,487
Technical Sentiment Signal: Sell
Current Market Cap: A$115.1M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.